A look at Exact Sciences Corporation’s acquisition by Abbott: review EXAS revenue growth, margins, and CRC/MRD screening ...
Hosted on MSN
Should You Buy Exact Sciences Stock Before Nov. 3?
Exact Sciences' most important product is driving solid revenue growth. It has launched several others that could help boost sales and jolt the stock. The company's long-term prospects look attractive ...
On Tuesday, Wave Life Sciences Ltd. (NASDAQ:WVE) revealed interim data from the ongoing Phase 2 FORWARD-53 study of WVE-N531 for Duchenne muscular dystrophy (DMD) patients amenable to exon 53 skipping ...
KIEV, UKRAINE - 2019/01/16: In this photo illustration, the Edwards Lifesciences Medical device company logo seen displayed on a smartphone. (Photo Illustration by Igor Golovniov/SOPA ...
The biotech earned an important fast-track review designation from a major regulator. This should speed the development (and potentially, commercialization) of one of its investigational treatments.
The stock of small-cap biotech Wave Life Sciences Inc. soared 51% Tuesday after the company reported positive interim data from a mid-stage trial of a treatment for the rare muscle disorder Duchenne ...
Madison, Wis.-based Exact Sciences saw shares increase 12 percent after Minnetonka, Minn.-based UnitedHealthcare said it would cover the company’s colon cancer screening test Cologuard, according to a ...
Exact Sciences Corp (NASDAQ:EXAS) reported fourth-quarter financial results after the market close on Wednesday. Here’s a look at the key details from the quarter. Q4 Earnings: Exact Sciences reported ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback